SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) today announced that its Board of Directors has elected Paulo
F. Costa as Chairman of the Board, effective immediately.
Mr. Costa was formerly President and Chief Executive Officer of Novartis
U.S. Corporation, where he held several other executive positions, including
Head of the Americas and President and Chief Executive Officer of Novartis
Pharmaceutical Corporation. Prior to joining Novartis, Mr. Costa worked at
Johnson & Johnson for 30 years, where he served as President of Janssen
Pharmaceutica, Executive Vice President, Global Franchise Development, and was
a member of Johnson & Johnson's Group Operating Committee. Mr. Costa has held
various sales and marketing positions and has more than 20 years of general
management experience, having launched 10 pharmaceutical products in various
therapeutic areas in the U.S. market. He was elected to Amylin's Board at the
Company's Annual Meeting of Stockholders on May 27, 2009.
"Our unanimous decision to name Paulo as Chairman reflects the Board's
confidence in his leadership abilities," said James R. Gavin III, M.D., Ph.D.,
Director and Chair of Amylin's Corporate Governance Committee. "Paulo brings a
fresh perspective to all aspects of Amylin's business at this important time
for the Company, and his expertise regarding operational and commercial
activities will be invaluable as we prepare for the launch of exenatide once
weekly. We continue to position Amylin to compete and win in the diabetes and
obesity markets. On behalf of the entire Board of Directors, we look forward
to working with Paulo in his new leadership role."
"It is with great honor and pleasure that I accept the position of
Amylin's Chairman," said Mr. Costa. "I am excited about working closely with
my fellow Directors to help Amylin successfully discover, develop and
commercialize innovative medicines to improve the lives of patients with
diabetes. By doing this well, we will deliver superior value to our
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN (pramlintide acetate) injection
and BYETTA (exenatide) injection. Amylin's research and development
activities leverage the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in San Diego,
California. Further information on Amylin Pharmaceuticals is available at
This press release contains forward-looking statements about Amylin, which
involve risks and uncertainties. The Company's actual results could differ
materially from those discussed due to a number of risks and uncertainties,
including that our clinical trials may not start when planned and/or confirm
previous results; our preclinical studies may not be predictive; our product
candidates may not receive regulatory approval; and inherent scientific,
regulatory and other risks in the drug development and commercialization
process. These and additional risks and uncertainties are described more fully
in the Company's most recently filed SEC documents, including its Form 10-Q.
Amylin undertakes no duty to update these forward-looking statements.
SOURCE Amylin Pharmaceuticals, Inc.
/CONTACT: Media: Anne Erickson, +1-858-754-4443,
firstname.lastname@example.org, or Financial: Michael York, +1-858-458-8602,
email@example.com, both of Amylin Pharmaceuticals, Inc./